Skip to Content

Watson 667 (Divalproex sodium delayed release 500 mg)

Pill imprint Watson 667 has been identified as Divalproex sodium delayed release 500 mg.

Divalproex sodium is used in the treatment of bipolar disorder; mania; migraine prevention; epilepsy; hyperekplexia (and more), and belongs to the drug class fatty acid derivative anticonvulsants. When treating epilepsy and manic episodes associated with bipolar disorder: There is positive evidence of human fetal risk during pregnancy. When treating migraine: Not for use in pregnancy. Divalproex sodium 500 mg is not a controlled substance under the Controlled Substance Act (CSA).

Divalproex sodium delayed release
Watson 667
500 mg
Elliptical / Oval
Prescription only
Drug Class:
Fatty acid derivative anticonvulsants
Pregnancy Category:
D - Positive evidence of risk - When treating epilepsy and manic episodes associated with bipolar disorder
X - Not for use in pregnancy - When treating migraine
CSA Schedule:
Not a controlled drug
Watson Laboratories, Inc.
National Drug Code (NDC):
Inactive Ingredients:
candelilla wax
silicon dioxide colloidal
croscarmellose sodium
FD&C Red No. 40
hydroxypropyl cellulose
hypromellose 2910 (15 mPa.s)
ferrosoferric oxide
lactose monohydrate
magnesium stearate
microcrystalline cellulose
propylene glycol
silicon dioxide
titanium dioxide
aluminum oxide

View Details Print Page Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2015, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.